Treatment Options for Diabetic Macular Oedema (DMO)

Key Takeaways

• Diabetic macular oedema (DMO) is a complication of diabetic retinopathy that causes vision impairment due to fluid buildup in the macula.

• Anti-VEGF injections are the first-line treatment for most patients with centre involving DMO

• Laser therapy and corticosteroids are alternative or adjunct options depending on disease severity and response.

• Early detection and consistent monitoring of diabetic retinopathy are essential to prevent vision loss.

Diabetic macular oedema (DMO) is one of the leading causes of vision loss among individuals with diabetes [1]. It occurs when fluid accumulates in the macula—the central part of the retina responsible for sharp, detailed vision. This condition develops as a complication of diabetic retinopathy, a progressive eye disease caused by prolonged high blood sugar levels.

Treatment options for diabetic macular oedema include anti-VEGF injections, corticosteroid therapy, laser treatment, and systemic diabetes control, all aimed at reducing retinal swelling and preserving vision.

Understanding the available treatments can help patients make informed decisions and actively participate in managing their eye health.

What Is Diabetic Macular Oedema?

Diabetic macular oedema occurs when damaged blood vessels in diabetic retinopathy leak fluid into the macula, leading to swelling and distorted vision [2]. This can result in blurred or wavy vision, difficulty reading, and reduced ability to recognize faces.

Not all patients with diabetic retinopathy will develop DMO, but those with poorly controlled diabetes or advanced stages of the disease are at higher risk. Regular eye screenings are crucial for early detection and timely intervention.

Anti-VEGF Injections: First-Line Treatment

Anti-VEGF (vascular endothelial growth factor) therapy is the most widely used treatment for DMO associated with diabetic retinopathy [3]. VEGF is a protein that promotes abnormal blood vessel growth and leakage. These medications are injected directly into the eye and work by:

• Reducing fluid leakage

• Stabilizing blood vessels

• Improving or maintaining vision

Patients typically receive a series of monthly injections initially, followed by less frequent treatments depending on their response. Anti-VEGF therapy has significantly improved outcomes for individuals with diabetic retinopathy, making it the gold standard for DME management.

Corticosteroid Therapy

Corticosteroids are another option for treating DMO, first line in certain patients with inflammatory biomarkers noted on OCT scans or in patients who do not respond adequately to anti-VEGF injections [4]. These medications help reduce inflammation and vascular permeability associated with diabetic retinopathy. Steroids may be administered as:

• Intravitreal injections

• Sustained-release implants

While effective, corticosteroids carry potential side effects such as increased intraocular pressure and cataract formation. Therefore, careful monitoring is necessary when using this treatment in patients with diabetic retinopathy.

Laser Photocoagulation

Before the widespread use of anti-VEGF therapy, laser photocoagulation was the primary treatment for DMO. It remains a valuable option in certain cases of diabetic retinopathy, particularly when the oedema is localized.

Laser treatment works by sealing leaking blood vessels and reducing fluid accumulation. Although it may not significantly improve vision, it can help stabilize the condition and prevent further deterioration.

In modern practice, laser therapy is often used in combination with other treatments for diabetic retinopathy to enhance outcomes.

Systemic Management of Diabetes

Effective control of blood sugar, blood pressure, and cholesterol plays a crucial role in managing DME and slowing the progression of diabetic retinopathy [5]. Key strategies include:

• Maintaining optimal blood glucose levels

• Managing hypertension

• Adopting a healthy diet and regular exercise routine

Systemic management not only supports eye treatments but also reduces the risk of other diabetes-related complications. Without proper control, even the best ocular treatments for diabetic retinopathy may have limited long-term success.

Treatment Comparison

Treatment Option	Mechanism of Action	Frequency	Key Benefits
Anti-VEGF Injections	Blocks VEGF to reduce leakage	Monthly initially	Improves and stabilizes vision
Corticosteroids	Reduces inflammation and swelling	Every few months	Useful in resistant cases
Laser Therapy	Seals leaking blood vessels	Usually one or few sessions	Prevents further vision loss
Systemic Control	Manages underlying diabetes	Ongoing	Slows progression of diabetic retinopathy

Factors Influencing Treatment Choice

The choice of treatment for DMO depends on several factors related to the severity of diabetic retinopathy and individual patient characteristics.

• Severity of Oedema: Mild cases may be monitored, while more advanced cases require immediate intervention.

• Response to Initial Therapy: Patients who respond well to anti-VEGF injections may continue this approach, while others may need alternative treatments.

• Patient Health and Preferences: Factors such as tolerance for injections, ability to attend frequent appointments, and overall health can influence treatment decisions in diabetic retinopathy.

Importance of Early Detection

Early detection of DMO is critical for preserving vision [6]. Regular eye examinations allow healthcare providers to identify changes associated with diabetic retinopathy before significant vision loss occurs. Screening methods include:

• Dilated eye exams

• Optical coherence tomography (OCT)

• Fundus photography

Timely diagnosis ensures that treatment can begin at an early stage, improving outcomes and reducing the risk of complications from diabetic retinopathy.

Living with Diabetic Macular Oedema

Managing DMO requires a long-term commitment to both medical treatment and lifestyle changes. Patients with diabetic retinopathy should work closely with their healthcare team to develop a comprehensive care plan. This includes:

• Attending regular follow-up appointments

• Adhering to prescribed treatments

• Monitoring vision changes at home

Support from family, healthcare providers, and diabetes educators can also play a vital role in maintaining eye health and overall well-being.

Conclusion

Diabetic macular oedema is a serious complication of diabetic retinopathy, but advances in treatment have made it more manageable than ever before. Options such as anti-VEGF injections, corticosteroids, laser therapy, and systemic diabetes control provide effective ways to reduce swelling and preserve vision.

By staying proactive with regular screenings and adhering to treatment plans, patients with diabetic retinopathy can significantly improve their chances of maintaining good vision and quality of life.

References

1. National Eye Institute. (2023). Diabetic retinopathy.https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy

2. American Society of Retina Specialists. (2024). Diabetic macular edema. https://www.asrs.org/patients/retinal-diseases/6/diabetic-macular-edema

3. Urbančič, M., et al. (2020). Anti-VEGF treatment of diabetic macular edema. Acta Ophthalmologica.https://pmc.ncbi.nlm.nih.gov/articles/PMC7125496/

4. Sanaka, S., et al. (2026). Therapeutic outcomes of anti-VEGF agents versus corticosteroids in diabetic macular edema.https://pmc.ncbi.nlm.nih.gov/articles/PMC12897139/

5. Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on long-term complications. New England Journal of Medicine, 329(14), 977–986.https://www.nejm.org/doi/full/10.1056/NEJM199309303291401

6. Bandello, F., et al. (2012). Evidence for anti-VEGF treatment of diabetic macular edema.https://pubmed.ncbi.nlm.nih.gov/22907145/